Revance Therapeutics (NASDAQ:RVNC) Now Covered by Analysts at StockNews.com

Stock analysts at StockNews.com assumed coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a report released on Tuesday. The brokerage set a “hold” rating on the biopharmaceutical company’s stock.

Several other research analysts have also recently commented on the stock. HC Wainwright reaffirmed a “neutral” rating and set a $6.60 target price on shares of Revance Therapeutics in a report on Friday, November 8th. Barclays lowered their price objective on Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating on the stock in a research note on Monday, December 23rd. Needham & Company LLC reiterated a “hold” rating on shares of Revance Therapeutics in a research report on Friday. Finally, Mizuho reduced their target price on Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating on the stock in a report on Tuesday, December 10th. Nine research analysts have rated the stock with a hold rating and one has issued a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $8.39.

Revance Therapeutics Price Performance

Shares of NASDAQ RVNC opened at $3.68 on Tuesday. The firm has a market cap of $384.16 million, a price-to-earnings ratio of -1.91 and a beta of 0.86. The stock’s fifty day moving average price is $3.47 and its two-hundred day moving average price is $4.57. Revance Therapeutics has a one year low of $2.30 and a one year high of $7.56.

Revance Therapeutics (NASDAQ:RVNC) last released its quarterly earnings results on Thursday, November 7th. The biopharmaceutical company reported ($0.37) EPS for the quarter, missing the consensus estimate of ($0.35) by ($0.02). The company had revenue of $59.88 million for the quarter, compared to analyst estimates of $67.73 million. On average, equities analysts anticipate that Revance Therapeutics will post -1.57 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Revance Therapeutics

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. FORA Capital LLC bought a new stake in shares of Revance Therapeutics during the 3rd quarter valued at about $54,000. Creative Planning bought a new stake in shares of Revance Therapeutics during the third quarter valued at approximately $56,000. Vanguard Personalized Indexing Management LLC acquired a new position in Revance Therapeutics during the second quarter worth $33,000. Accredited Investors Inc. acquired a new position in Revance Therapeutics during the 3rd quarter valued at about $67,000. Finally, Hsbc Holdings PLC purchased a new position in shares of Revance Therapeutics during the second quarter valued at approximately $38,000. 97.70% of the stock is currently owned by institutional investors and hedge funds.

Revance Therapeutics Company Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.